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Abstract
Submandibular gland peptide-T (SGP-T) is a potent anti-chemotactic agent for human neutrophils possessing anti-inflammatory
properties. Biologically active analogues of SGP-T have been synthesized and a biotinylated form (KG6-SGP-T; Bio-KG6-SGP-T) was
utilized to identify binding sites on isolated human neutrophils. Neutrophils incubated with Bio-KG6-SGP-T followed by phycoerythrin
(PE)–avidin secondary reagent were fixed and visualized using histochemistry and flow cytometry. At doses of 10 8 and 10 9 M, Bio-KG6-
SGP-T was shown to bind to neutrophils. The binding of Bio-KG6-SGP-T, at doses of 10
 8 and 10 9 M, to neutrophils was abolished by a
100-fold excess of non-biotinylated peptide (KG6-SGP-T), but not by 100-fold excess of SGP-T. However, all peptides, dose-dependently
reduced the binding of a CD16b antibody (LNK16 clone) to isolated human neutrophils. This discrepancy probably results from different
preferred conformations for Bio-KG6-SGP-T, KG6-SGP-T and SGP-T, since exhaustive conformational searches revealed a high degree of
overlap between a-Bio-KG6-SGP-T and KG6-SGP-T that was not seen with SGP-T.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Submandibular gland peptide-T (SGP-T; sequence =
NH3
+-TDIFEGG-COO) is an anti-inflammatory peptide
significantly reducing endotoxic [1] and anaphylactic reac-
tions [2,3], and inhibiting neutrophil chemotaxis [4,5].
Even with this potent biological activity, the search for
SGP-T receptors has been encumbered by the absence of an
amino acid that can readily be labeled. Various analogues
of SGP-T have been synthesized with moieties that can be
labeled, and one of them, KG6-SGP-T (sequence =NH3
+-
KGGGGGGTDIFEGG-COO), retains the biological
activity displayed by SGP-T in both its native and bio-
tinylated form (Bio-KG6-SGP-T) [3]. Hence, Bio-KG6-
SGP-T may be a tool for receptor localization and isolation
in a manner similar to that used for other peptides such as
endothelin [6], gonadotropin releasing hormone [7] and
insulin [8].
Recently, Mathison et al [5] demonstrated that SGP-T-
related peptides inhibit the expression of CD11b and CD16b
on neutrophils exposed to platelet-activating factor (PAF).
From these studies, it was hypothesized that a receptor
exists on neutrophils for SGP-T, although its existence has
not been conclusively demonstrated. In this study, we show
that Bio-KG6-SGP-T binds specifically to neutrophils.
However, this binding appears to be distinct from that by
SGP-T.
2. Methods
All protocols were approved by the Calgary Regional
Health Authority.
2.1. Peptide synthesis and preparation
Peptides were synthesized at the University of Calgary
Protein Synthesis Facility (Calgary, AB), and at Core Labo-
ratories, Queen’s University (Kingston, ON). Bio-KG6-SGP-
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T was prepared using synthesized KG6-SGP-T and a bio-
tinylation kit BK-200 (Sigma Chemical, St. Louis, MO)
following the included protocol with slight modifications.
Briefly, KG6-SGP-T was dissolved in PBS to which was
added a 15 M excess of biotin-disulfide N-hydroxysuccini-
mide ester dissolved in N,NV-dimethylformamide. Reagents
were gently mixed for 60 min at room temperature. Bio-
KG6-SGP-T was purified by HPLC at the University of
Calgary protein synthesis facility. Bio-KG6-SGP-T eluted
in two distinct peaks corresponding to an earlier mono- and
later di-biotinylated fractions. The mono-biotinylated pep-
tide was isolated and used.
2.2. Neutrophil isolation
Blood was drawn from healthy, drug-free, human volun-
teers and diluted to 40 ml with PBS. The diluted blood was
layered over 10 ml of Lympholyte mammal (Cedarlane,
Hornby, ON) and centrifuged at 300 g for 15 min at 4
jC. The supernatant was aspirated and discarded and the
pellet resuspended in 50 ml of lysis buffer. The extent of lysis
was determined visually by noting the change from opacity to
translucency, and cells were then centrifuged at 180 g for
10 min at 4 jC. Lysis was repeated as before and neutrophil
viability was assessed by Trypan blue exclusion and found to
be greater than 97%. Neutrophils were kept on ice in PBS
until used.
2.3. Expression of CD16b
Neutrophils were isolated as previously described. Cells
were then incubated with KG6-SGP-T at room temperature
for 15 min. PAF was then added at 10 9 M for 15 min at 37
jC to stimulate the neutrophils. PBS was added to terminate
PAF stimulation and the cell suspension was spun at 1300
rpm (approximately 300 g) in an Hermle Z 360 K cen-
trifuge (Mandel Scientific, Guelph, ON) for 6 min at 4 jC,
and the washing step was repeated. The following anti-
bodies were used: mouse anti-human the LNK16 clone of
CD16b IgG-fluorescein isothiocynate (FITC) (Serotec,
Raleigh, NC), and mouse anti-human 1D3 clone of
CD16b IgM-FITC (Immunotech, Burlington, ON). These
antibodies were added to minimum volume and the cells
incubated for 30 min at 4 jC. Cells were then washed in
PBS and immediately assayed by flow cytometry. These
two antibodies were chosen because they bind to distinct
sites on CD16 [9].
2.4. Flow cytometry
The flow cytometry analysis was performed on a Becton-
Dickinson FACScan (Franklin Lakes, NJ). Sample sizes of
150 Al were scanned and the data was collected using Cell-
quest on a Powermac 8100. Analysis of data was done on a
PC using WinMDI v2.8 (Scripps Research Institute, La Jolla,
CA).
2.5. In vitro binding
Neutrophils (1.0 106) were placed in wells on a 96-well
polypropylene plate and brought to 2 AM Ca2 + in PBS.
Peptide was added to each well as follows: cells alone, KG6-
SGP-T at 10 6 M, Bio-KG6-SGP-T at 10
 8, 10 10, 10 12
and 10 6 M KG6-SGP-T or 10
 6 M SGP-T with 10 8 M
Bio-KG6-SGP-T. Cells were incubated for 10 min at 37 jC
with PAF (10 9 M), or PBS, as a control, for 1 min at 37 jC.
Fig. 1. Streptavidin–PE in the presence of neutrophils alone (Control) and
the indicated doses of Bio-KG6-SGP-T and KG6-SGP-T. All slides are
viewed in duplicate under white light (left column) and rhodamine filters
(right column). In both the Control (a) and KG6-SGP-T at 10
 6 M (b)
slides, note the absence of fluorescence corresponding to any of the cells
shown under light. In contrast, almost all cells pictured for Bio-KG6-SGP-T
at 10 8 M (c) are visibly fluorescing. In the presence of KG6-SGP-T at
10 6 M and Bio-KG6-SGP-T at 10
 8 M (d), the percentage of labelling
evident under fluorescence has decreased from that exhibited for Bio-KG6-
SGP-T alone. These results are quantified in Fig. 2.
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When PAF was added, incubation was performed either
prior to peptide incubation or following peptide incubation.
Two hundred microliters of 2% paraformaldehyde was then
added to each well and the plate was incubated at room
temperature for 10 min. Neutrophils (5.0 105) were placed
on chrome-alum coated slides and air dried. Slides were
washed in double-distilled water followed by a wash in 1%
BSA for 10 min. Slides were then incubated with strepta-
vidin–PE (Pharmingen, San Diego, CA) for 10 min and
examined using fluorescence microscopy on a Olympus
PX60 with an Olympus mercury lamp BH2-RFL-T3 (Olym-
pus America, Lake Success, NY) under white light and
rhodamine filters.
2.6. Molecular modeling and exhaustive conformational
search
Theoretical calculations were performed on an Intel
workstation using HyperChem version 6.0 (Hypercube,
Gainsville, FL). Peptide structures were built using the
Database Amino Acids option. An exhaustive Conforma-
tional Search was performed. All torsional angles within
the peptides, consisting of all atoms excluding hydrogen,
were selected and named. Torsions were allowed to vary
F 180j and all torsions were allowed to be distorted
simultaneously. Rings were also defined but were excluded
from deformation. Pre-optimization, conformations were
skipped if atoms were found to be closer than 0.5 A˚ or
if the torsions were within 15j of the previously attempted
conformation. Post-optimization, conformations were dis-
carded if any of the chiral centers had been changed within
the conformation. Conformations were then analyzed to
determine if they were duplicates of previously identified
structures. If the energy was within 0.05 kcal/mol, or the
all atom root mean square deviation (RMSD), excluding
hydrogen, was within 0.5 A˚ of a previously defined
conformation, the two conformations were deemed to be
the same.
Energyminimization was performed using the AMBER96
force-field and the conjugate gradient (CG) and adopted
Polak-Ribiere (PR) algorithm. Further, minimization was
carried out in vacuo (dielectric, e= 1) in order to simulate a
nonpolar lipid environment such as that present in the vicinity
of a membrane receptor [10–13]. Electrostatic and Van der
Waal’s forces were scaled by a factor of 0.5 with no cutoffs
used. Minimization was allowed to proceed for 10000 cycles
in order to ensure that most conformations would converge to
a gradient of less than 110 3 kcal/(A˚ mol). Only 1000
Fig. 2. The percentage of cells labeled by streptavidin–PE for Control, KG6-SGP-T at 10
 6 M, Bio-KG6-SGP-T at 10
 8, 10 10 and 10 12 M, and KG6-SGP-
T and Bio-KG6-SGP-T at the competition doses of 10
 6 and 10 8 M, respectively (e), *indicates P< 0.01, **P< 0.001, n= 3. Stacked bars correspond to
standard error.
Table 1
Effects of peptide administration on 10 9 M PAF-induced increases in CD16b-LNK16 expression in human neutrophils
Concentration SGP-T KG6-SGP-T Bio-KG6-SGP-T
(M)
Percentage of
control (%)
DMFIa Percentage of
control (%)
DMFI Percentage of
control (%)
DMFI
10 9  0F 10  57F 36  6F 3  54F 25 8F 7 51F 57
10 11  16F 6  115F 41*  14F 4*  121F 46*  12F 7*  77F 43*
10 13  8F 5  50F 31  21F 6*  173F 73*  16F 8*  135F 68*
a Change in mean fluorescence intensity.
*P< 0.05 relative to no change; n= 5–9.
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conformations within 24 kcal of the minimum energy struc-
ture were kept for analysis. The criteria for terminating the
search was either 1106 iterations, or attempted conforma-
tions, or 1105 completed optimizations of proposed struc-
tures. Resultant structures were ranked by free energy from
lowest to highest. Only conformations that were 24 kcal/mol
or less above the optimal, that is the lowest energy structure,
were kept and indexed. Low energy is directly equivalent to
low index number.
Subsequently, a pair-wise comparison of all derived
KG6-SGP-T conformations with all Bio-KG6-SGP-T struc-
tures was performed. The optimal pair, as determined by
conformational free energy, and an all-atom RMSD, hydro-
gen exclusive, was determined. From this pair, the best Bio-
KG6-SGP-T conformation, with respect to KG6-SGP-T, was
used as the comparison structure for the other peptides.
Briefly, the equivalent atoms were extracted from the Bio-
KG6-SGP-T structure and an RMSD determined. In this
way, the structure of SGP-T, which would correspond to the
optimal structure of Bio KG6 SGP T, could be identified and
compared to determine whether they possess similar con-
formations. Further, the sequence Thr-Asp-Ile-Phe-Glu,
defined as the key sequence as these were the non-Gly
residues present in all three peptides, was used as the
comparison sequence and RMSDs were performed using
only these residues.
2.7. Statistical analysis
Data are expressed as meanF S.E. The data were
analyzed using one-way analysis of variance (ANOVA)
and differences between groups were calculated using
Student’s t-test for unpaired samples. Data was considered
significant at P < 0.05. Correlation coefficients for biolog-
ical activity with respect to dipole vectors of the peptides
was made using a multivariate exponential curve fitting
function available in Microsoft Excel.
3. Results
3.1. Histochemical labeling
Maximal binding of Bio-KG6-SGP-T to neutrophils
occurred at a concentration of 10 8 M (Figs. 1c and 2),
and levels of binding decreased in a dose-dependent manner
down to 10 12 M (Fig. 2). Bio-KG6-SGP-T binding was
displaced by a 100-fold excess of KG6-SGP-T (Figs. 1d and
2), and did not occur in the absence of peptides (Figs. 1a and
2), nor with KG6-SGP-T alone (Figs. 1b and 2). However,
binding of Bio-KG6-SGP-Twas not affected by the presence
of a 100-fold excess of SGP-T (Fig. 2). Neutrophils incu-
bated without streptavidin–PE displayed negligible auto-
fluorescence (Figs. 1a and 2), and neither the order of
addition of PAF nor its presence or absence affected binding
(not shown).
3.2. Binding of the CD16B antibodies LNK16 and 1D3
To determine whether KG6-SGP-T and Bio-KG6-SGP-T
had similar biological properties to SGP-T, we examined
their effects on the binding of two antibodies with different
Fig. 3. Stereoscopic images of the best KG6-SGP-T conformation (a), and the closest fit a-Bio-KG6-SGP-T conformation index 6 (b). The two structures have
been overlayed (c) to determine their total RMSD, the backbone overlay is displayed to the right of the overlay. KG6-SGP-T is displayed in grey while a-Bio-
KG6-SGP-T index 6 is displayed in black.
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binding epitopes to isolated human neutrophils. SGP-T is
known to reduce, exclusively, the binding of the LNK16
antibody and not that of 1D3 [5] as stimulated by 10 9 M
PAF. SGP-T, KG6-SGP-T and Bio-KG6-SGP-T were effec-
tive at reducing LNK16 binding at a dose of 10 13 M.
(Table 1) However, none of the peptides altered the bind-
ing of the 1D3 antibody.
3.3. Exhaustive conformational search
The pair-wise comparison of 252 identified KG6-SGP-T
conformations with 594 a-Bio-KG6-SGP-T structures
yielded a grid of 149688 RMSD. Of these 149 688
comparisons, the lowest overall RMSD of 2.42 A˚ indicated
conformation 207 of KG6-SGP-T and 482 of a-Bio-KG6-
Fig. 4. Stereoscopic images of the best SGP-T conformation (a), and the conformation yielding the closest fit to a-Bio-KG6-SGP-T index 6, SGP-T index 158
(b). The first structure has been overlayed with a-Bio-KG6-SGP-T (c) while the optimal fit structure from (b) is overlayed in (d) to determine their total RMSD,
the backbone overlay is displayed to the right of the overlay. KG6-SGP-T is displayed in red while a-Bio-KG6-SGP-T index 6 is displayed in blue. Note in (c)
the interweaving of the backbone which is notably absent in (d).
Table 2
RMSD of the equivalent sequences found in the reference peptide (TDIFE) and the comparison peptide shown for optimal conformations of a given peptide as
well as the closest fitting conformations
Reference peptide (R) Comparison peptide (C) Peptide index (R, C)a RMSD (A˚)b Key sequence RMSD (A˚)c
KG6-SGP-T a-Bio-KG6-SGP-T 207, 482 2.42 1.82
KG6-SGP-T a-Bio-KG6-SGP-T 1, 1 5.22 3.06
KG6-SGP-T a-Bio-KG6-SGP-T 1, 6 2.95 1.21
a-Bio-KG6-SGP-T SGP-T 6, 1 3.14 2.8
a-Bio-KG6-SGP-T SGP-T 6, 158 1.95 1.43
a-Bio-KG6-SGP-T SGP-T 6, 753 2 1.46
a Peptide index obtained from the exhaustive conformational search, lower indices are indicative of lower energy structures. Index are given as Reference
peptide (R) followed by the Comparison peptide (C).
b RMSD obtained from comparison of equivalent sequence found in both peptides only.
c RMSD obtained from comparison of the key sequence of Thr-Asp-Ile-Phe-Glu only.
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SGP-T were the most closely related structures. However,
the lowest key sequence RMSD of 1.21 A˚ indicated
conformation 1 of KG6-SGP-T and 6 of a-Bio-KG6-
SGP-T. This later pairing is likely the most biologically
relevant pairing of KG6-SGP-T (Fig. 3a) and a-Bio-KG6-
SGP-T (Fig. 3b). Although this pairing exhibited an
RMSD of 2.95 A˚ (Fig. 3c), this deviation also represented
a drop of 22.6 kcal/mol for KG6-SGP-T and 19.7 kcal/mol
for a-Bio-KG6-SGP-T from the most closely related pair-
ing indicated by RMSD. The lowest RMSD and key
sequence RMSD for SGP-T from the equivalent sequence
of Bio-KG6-SGP-T was index 158 of SGP-T (Fig. 4b)
followed by indices 753 and 513. These correspond to
conformations 3.00, 5.82, and 4.89 kcal/mol above the best
conformation identified. The RMSD and key sequence
RMSD are summarized in Table 2.
The exhaustive search of q-Bio-KG6-SGP-T yielded
only 49 conformations in a window extending 24 kcal
above the optimal structure. Index 1, the best of these
conformations, was found to be approximately 60 kcal/mol
less favorable than the optimal a-Bio-KG6-SGP-T confor-
mation. This result suggests that q-Bio-KG6-SGP-T prob-
ably does not achieve a conformation capable of binding to
neutrophils.
4. Discussion
It has been previously demonstrated that neutrophil
functions such as chemotaxis and superoxide anion produc-
tion [4] as well as leukocyte rolling [14] are inhibited by
SGP-T. Using Bio-KG6-SGP-T, we have demonstrated that
this peptide binds to neutrophils, confirming these cells as
potential targets for salivary gland peptides. This binding is
specific and displaceable by KG6-SGP-T as demonstrated
by histology (Fig. 1). The lack of a detectable effect of PAF
on Bio-KG6-SGP-T binding is of note when considered with
changes in the binding of LNK16 antibody induced by these
peptides. Histology indicates that PAF is not involved with
the binding of Bio-KG6-SGP-T to isolated neutrophils. In
contrast, modification of LNK16 antibody binding was
dependent on stimulation by PAF, and doses as low as
10 11 M SGP-T were able to attenuate the PAF-induced
increase in cell surface expression. The key difference
between the techniques is that histological optical assess-
ment assay detects binding of biotinylated ligand, whereas
fluorescence-based FACs assay measures the binding of
antibody to CD16b.
Despite the ability of a 100-fold excess of KG6-SGP-T to
abolish observable binding of Bio-KG6-SGP-T, 100-fold
excess of SGP-T was without effect. This apparent lack of
competition suggests that the two peptides may actually
interact with different binding sites. However, as noted in
Table 1, SGP-T, KG6-SGP-T and Bio-KG6-SGP-T attenuate
LNK16 antibody binding. Hence, this apparent discrepancy
may be due to binding of KG6-SGP-T and Bio-KG6-SGP-T
to a site distinct from that to which SGP-T binds, although
both molecules are capable of hindering the binding of
LNK16 antibody to PAF stimulated neutrophils.
In humans, CD16 is expressed in two distinct but
highly homologous forms [15]. CD16a, expressed predom-
inantly on monocytes, NK cells, macrophages and others
[9,16], is transmembrane-linked receptor that associates
with a number of subunits to exert its effects. Conversely,
CD16b is truncated, resulting in a glycosylphosphatidyli-
nositol anchored form, which does not require association
with subunits to exert its actions. It is this later form that is
found exclusively on neutrophils [15]. The antibodies used
bind to two distinct sites, LNK16 recognizing a sequence
in one of the extracellular loops of both CD16a and
CD16b. The 1D3 binding site is located in the extracellular
domain close to the membrane anchor at a site that appears
specific for CD16b. The use of the 1D3 epitope afforded
an opportunity to determine whether decreases in observed
LNK16 binding was due to shedding of the CD16b into
the soluble form [17] or whether the peptides were
modifying antibody binding to intact, surface-bound,
CD16b on neutrophils. The latter seems to be the case
as peptide treatment exerts no effect on 1D3 binding,
which is closer to the carboxyl-terminal of CD16b than
the LNK16 binding site. This epitope is distal to the serine
protease cleavage site that generates soluble CD16b [18].
Hence, the binding of the peptides is likely inducing a
conformational change in CD16b, which masks the
LNK16 epitope or, conversely, binding close enough to
the epitope in order to mask it from the antibody.
Recently, we were able to achieve very high correlations
between biological activity of submandibular gland tripep-
tides related to SGP-T and structures simulated in vacuo
[13]. However, in the current study, a larger set of con-
formations was considered, and by completing an exhaus-
tive search of the conformational space available to each of
the peptides, a key conformation was identified. Of partic-
ular note is the relationship between the minimum energy
structure of KG6-SGP-T (Fig. 3a) and its small RMSD as
compared to a low-energy conformation of a-Bio-KG6-
SGP-T. Although the minimal energy structure found for
KG6-SGP-T corresponded to the sixth best a-Bio-KG6-
SGP-T (Fig. 3b) structure and not to the minimum, the
relative position of the biotin spacer arm is the key contrib-
utor to the differences in the low energy Bio-KG6-SGP-T
structures. In fact, when only the key sequence (Thr-Asp-
Ile-Phe-Glu) is used for comparison, the RMSD between
these molecules is the closest fit at only 1.22 A˚ and this
deviation is attributable to small rotations in the sidechains
with an almost perfect backbone overlay. This pairing,
energetically the most relevant, indicates that the sixth
conformation of Bio-KG6-SGP-T is likely the active form
of the peptide. When pairwise comparison of this structure
with all of the obtained SGP-T conformations was per-
formed, the resulting fits indicated that the lowest energy
structure was a poor fit to that of Bio-KG6-SGP-T. Indeed,
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the best fits were obtained with structures that were between
3 and 6 kcal/mol or more above the optimal conformation.
As can be seen in the overlay (Fig. 4c) of a-Bio-KG6-SGP-
T (Fig. 3b) and the best SGP-T conformation (Fig. 4a), the
backbones interweave such that side chains of residues like
Ile and Asp are pointed in diametrically opposed directions
between peptides and possess an overall RMSD of 3.14 A˚.
When only the key sequence is used for comparison, the
resultant RMSD only falls to 2.80 A˚. In contrast, the overlay
of the best fitting structure (Fig. 4d), which gives a good fit
with an overall RMSD of 1.95 A˚ and a key sequence RMSD
of 1.43 A˚, lies approximately 3 kcal/mol above the best
conformation. There are 157 conformations of lower energy
than this optimal fit structure, making it improbable that this
relatively high-energy structure is maintained. Thus, it is not
difficult to understand why SGP-T is unable to displace
bound Bio-KG6-SGP-T.
The relevance of energy calculations for the determina-
tion of the preferred peptide conformation can only be
evaluated after the isolation and characterization of the
binding site/receptors for SGP-T and its related peptides.
Hence, the possibility exists that these peptides may inter-
act with several different binding sites. The C-terminal
amidated derivative of the tripeptide with similar biological
activities to SGP-T (i.e. D-Phe-D-Glu-Gly; feG) is 35 times
more potent than the native carboxyl peptide in inhibiting
perturbations of intestinal motility caused by lipopolysac-
charide [19], and is effective in preventing lipopolysaccr-
ide-induced accumulation of neutrophils in heart [20].
Thus, SGP-T and its derivatives behave in a manner similar
to several other peptide hormones, such as melanocyte
stimulating hormone (MSM), gastrin, cholecystokinin and
substance P, where C-terminal amides are essential for full
biological activity [21,22]. On the other hand, C-terminal
amidation abolishes the anti-anaphylactic activity of feG
and SGP-T [23], an observation consistent with multiple or
allosteric binding sites for these peptides. As a case in
point, the melanotropin peptide family consists of a-, h-,
and g-MSM and adrenocorticoptropin, which recognize
four of the five melanocorticotropin receptors (hMC1R,
hMC3-5R) [24–26]. Only hMC2R is activated exclusively
by ACTH [26]. Similarly, three neurokinin receptors have
been identified with preferred, but not exclusive binding for
the three mammalian neurokinin peptides, substance P,
neurokinin A and neurokinin B [27]. The complexities of
receptor–ligand interactions are apparent with the NK1
receptor, which possesses two types of nonstoichiometric
binding sites with distinct pharmacological profiles [28].
Similar complexities may eventually be revealed for the
SGP-T receptors.
When taken in context of the observed decrease in
detectable LNK16-CD16b binding coupled with the absence
of an affect on 1D3-CD16b binding, the computational data
suggests that the binding of the peptides induce a conforma-
tional change at the binding site of the LNK16 epitope.
Further, SGP-T may bind to an allosteric site distinct from
that used by KG6-SGP-T and Bio-KG6-SGP-T and thus
SGP-T cannot displace the Bio-KG6-SGP-T, although all
peptides mask, in some manner, the LNK16 epitope and
thereby prevent the binding of the LNK16 antibody. Further
studies are required to determine if CD16b is the actual
binding protein for SGP-T and its analogues, or whether
binding to another protein which interacts with CD16b so to
cause the masking of the LNK16 binding site.
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